A groundbreaking study from Samsung Medical Center reveals that proton therapy could transform treatment options for a group of lung cancer patients who have long been considered too fragile for standard radiation. Researchers found that patients with both lung cancer and idiopathic pulmonary fibrosis (IPF), a chronic condition where lung tissue progressively hardens, can now pursue curative treatment with significantly lower risk of severe complications.

What Is Idiopathic Pulmonary Fibrosis and Why Does It Complicate Lung Cancer Treatment?

Idiopathic pulmonary fibrosis is a disease of unknown cause in which the lungs gradually become scarred and stiff, making it harder to breathe and transfer oxygen into the bloodstream. Patients with IPF face a higher risk of developing lung cancer than the general population. The real challenge emerges when both conditions occur together: standard X-ray radiation therapy, the typical lung cancer treatment, can cause severe damage to already-compromised lungs.

When IPF patients receive conventional radiation therapy, their damaged lungs cannot tolerate the radiation dose. This leads to a dangerous complication called radiation pneumonitis, where lung tissue becomes inflamed and deteriorates rapidly. Research shows that 20 to 50 percent of IPF patients undergoing X-ray radiotherapy experience severe radiation pneumonitis, often forcing them to abandon treatment altogether.

How Does Proton Therapy Work Differently Than Standard Radiation?

Proton therapy uses a fundamentally different approach to target cancer cells. Instead of X-rays, the treatment accelerates protons, tiny particles, to extremely high energy levels and directs them at tumors. The key advantage lies in how protons behave: they release most of their energy concentrated precisely at the tumor site, then their energy drops off sharply beyond that point. This characteristic, called the Bragg peak, means far less radiation exposure to healthy lung tissue surrounding the cancer.

The Samsung Medical Center research team evaluated 41 patients with non-small cell lung cancer accompanied by IPF, treated between June 2020 and August 2023. The participants had a median age of 70 and severely impaired lung function, with a lung diffusing capacity for carbon monoxide (DLCO), a measure of how well oxygen moves from the lungs into the blood, at only about 45 percent of normal levels. This was a high-risk group by any standard.

What Were the Key Results for Early-Stage Lung Cancer Patients?

The results were striking. Among 32 early-stage lung cancer patients treated with proton therapy, only 9.4 percent developed grade 3 or higher severe radiation pneumonitis. This represents a dramatic reduction compared to the 20 to 50 percent incidence seen with conventional X-ray therapy. Beyond safety, the treatment outcomes were also favorable: the one-year overall survival rate for early-stage patients reached 80.6 percent, and the one-year local tumor control rate for all patients was 93.2 percent.

"Lung cancer accompanied by idiopathic pulmonary fibrosis has been a blind spot in care because treatment itself is so challenging," said Professor Noh Jae Myoung. "This study provides evidence that early-stage patients can safely pursue a curative approach with proton therapy."

Professor Noh Jae Myoung, Department of Radiation Oncology, Samsung Medical Center

When Should Patients Be Cautious About Proton Therapy?

The research team emphasized that results vary significantly depending on cancer stage and IPF severity. For patients with stage III or more advanced lung cancer, the safety profile changes considerably. Among nine stage III patients in the study, four, or 44.4 percent, developed severe radiation pneumonitis even after proton therapy. In patients with both severe IPF and stage III lung cancer, the risk climbed even higher to 57.1 percent.

Additionally, when proton therapy was combined with chemotherapy, the incidence of radiation pneumonitis rose to 50 percent, compared to just 6.5 percent in patients treated with radiation alone. These findings suggest that combination approaches require careful consideration and may not be appropriate for all patients.

Steps to Understanding Your Treatment Options With IPF and Lung Cancer

• Assess Your Cancer Stage: Early-stage lung cancer patients with IPF show the most favorable outcomes with proton therapy, with only 9.4 percent experiencing severe complications compared to historical rates of 20 to 50 percent with conventional radiation.
• Evaluate Your Lung Function: Your doctor will measure your DLCO score and overall pulmonary capacity to determine whether your lungs can tolerate any form of radiation therapy and which approach carries the lowest risk.
• Consider Treatment Combinations: If chemotherapy is part of your treatment plan, discuss with your oncology team whether proton therapy alone, conventional radiation, or chemotherapy-only approaches may be safer given your specific situation.
• Discuss Personalized Treatment Strategies: The research team is developing individualized treatment criteria that weigh both cancer stage and IPF severity, so ask your care team whether you might be a candidate for this emerging approach.

"For patients with idiopathic pulmonary fibrosis, choosing radiation therapy has always meant accepting considerable risk," explained Professor Pyo Hong-ryul. "If we establish personalized treatment strategies that take into account both cancer stage and the severity of idiopathic pulmonary fibrosis, more patients will be able to access treatment opportunities."

Professor Pyo Hong-ryul, Department of Radiation Oncology, Samsung Medical Center

What Comes Next for This Treatment Approach?

The Samsung Medical Center research team plans to develop more refined personalized treatment criteria by enrolling additional patients and conducting longer follow-up studies. Their goal is to create clear guidelines that help oncologists determine which IPF patients with lung cancer are best suited for proton therapy, conventional radiation, or other treatment options based on both cancer stage and fibrosis severity.

The study results were published in Radiotherapy and Oncology, the official journal of the European Society for Radiotherapy and Oncology, lending significant credibility to these findings within the international medical community. For the estimated population of IPF patients who develop lung cancer, this research opens a door that has long been closed, offering hope that a serious diagnosis no longer automatically means forgoing curative treatment.